- Adding the monoclonal antibody nimotuzumab to intensity-modulated radiotherapy (IMRT) is associated with improved survival outcomes of patients with stage III-IVb nasopharyngeal carcinoma (NPC).
Why this matters
- Treatment outcomes for NPC are often unfavorable, necessitating new options.
- At a median follow-up of 74.78 months, overall mortality was 16.03%, the locoregional failure rate was 9.32%, the distant failure rate was 9.73%, and 1.34% of patients experienced locoregional failure and distant metastases.
- Nimotuzumab+IMRT was associated with improved 5-year distant metastasis-free survival (DMFS; 93.09% vs 85.61%; P=.012) and OS (88.91% vs 78.30%; P=.006) compared with IMRT alone.
- Nimotuzumab+IMRT and IMRT alone were associated with similar 5-year locoregional relapse-free survival (85.34% vs 89.79%; P=.156) and PFS (79.96% vs 77.99%; P=.117).
- Nimotuzumab was independently associated with DMFS (HR, 2.317; P=.010) and OS (HR, 2.125; P=.004) in multivariate analysis.
- 730 patients with stage III-IVb NPC, 184 treated with nimotuzumab+IMRT and 546 with IMRT alone, were analyzed for survival outcomes after propensity matching.
- Funding: None.
- Retrospective study.